转-ε-viniferin的葡萄糖化物代谢物降低了甘油的积累在肝脏肥胖症的体外模型中
Pauline Beaumont1,2, Samuel Amintas3,4, Stéphanie Krisa1,2
1UMR 1366, Univ. Bordeaux, Bordeaux INP, INRAE, ISVV, 33140, Villenave d'Ornon, OENO, France.
Journal of physiology and biochemistry
|July 31, 2024
概括
葡萄树木中的一种化合物trans-ε-viniferin显示出对脂肪肝疾病的承诺. 它的葡萄糖类代谢物trans-ε-viniferin-2-glucuronide通过影响肝细胞中的脂肪代谢,有效降低甘油三.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 葡萄树木中的复星二元体trans-ε-viniferin在体内表现出对肝硬化症的保护作用.
- 转基因维尼费林的生物可用性较差,限制了其治疗潜力.
- 肝硬化或脂肪肝病是一个日益严重的健康问题,需要新的治疗策略.
研究的目的:
- 在肝脏肥胖症的体外模型中研究trans-ε-viniferin及其glucuronide代谢物的抗肥胖潜力.
- 阐明这些化合物的抗静态作用背后的作用机制.
- 确定哪些代谢物有助于观察到的保护作用.
主要方法:
- 利用用棕酸治疗的AML-12细胞来建模肝硬化症.
- 在用转基因维尼费林及其葡萄糖类化合物治疗后评估细胞活力和甘油三积累.
- 采用实时PCR和Western Blot来分析分子机制.
- 细胞和介质中的量化化合物水平.
主要成果:
- 转-ε-viniferin-2-glucuronide 显示出显著的降低甘油三的特性.
- 这种代谢物调节了新的脂质生成,脂肪酸吸收和甘油三组合.
- 其他葡萄糖化物代谢物和母化合物对细胞活力和脂肪有不同的影响.
- 成功量化细胞和细胞外环境中的化合物.
结论:
- 转-ε-viniferin-2-glucuronide通过影响关键的脂质代谢途径具有显著的抗稳定性活性.
- 转-ε-viniferin的葡萄糖化物代谢物可能是先前在体内观察到的抗静态效应的原因.
- 这项研究突出显示了trans-ε-viniferin代谢物的治疗潜力,用于治疗肝硬化症.
相关概念视频
Phase II Reactions: Glucuronidation
355
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
355
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Hepatic Drug Excretion: Influencing Factors
105
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
105
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
613
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
613
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K


